STAT August 8, 2024
Allison DeAngelis, Elaine Chen

Why did Novo Nordisk pull its paperwork to expand the use of Wegovy for a common type of heart failure? How will we know if the the government gets a good deal in the first round of drug pricing negotiations? And has Allison thought about anything other than venture capital for the last couple of months?

We discuss all that and more on this week’s episode of “The Readout LOUD.” STAT’s Washington Correspondent John Wilkerson joins us to discuss the first round of drug pricing negotiations under the Inflation Reduction Act, which will wrap up by September 1. We also cover the latest news in the life sciences including the merger of AI...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Conferences / Podcast, Pharma, Pharma / Biotech, Trends
JP Morgan Annual Healthcare Conference 2025: What are the key talking points likely to be?
Biden administration proposes Medicare coverage for weight loss drugs: 10 things to know
Proposed Coverage of Anti-Obesity Drugs in Medicare and Medicaid Would Expand Access to Millions of People with Obesity
Medicare and Medicaid would cover Ozempic, Wegovy under new Biden rule
Key Trends in the Evolution of PBMs and Their Future Impact on Drug Pricing and Pharmacy Operations

Share This Article